Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
763.710.29%
QQQ
716.920.2%
BTC/USD
79198.180.9497%
DIA
524.390.69%
GLD
405.111.35%
TLT
82.230.04%

Alpha Tau Medical Ltd

DRTSNASDAQ
Trade with Public
Trade with Public
$14.87
0.02520.17%
Last update: Sep 9, 8:46 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Alpha Tau Medical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alpha Tau Medical (DRTS).

Price Target Range — 13 Quarters

Analyst Consensus — 5 Analysts

4Buy
1Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$14Upside to Avg. PT-4.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 3, 2026BarclaysLukas ShumwayPT RaiseOverweight$17→$30
Aug 11, 2026HC Wainwright & Co.Yi ChenPT RaiseBuy$15→$16
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30

Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $17 to $30.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16

HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $17

Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $15 to $17.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved